[(16Z,18Z)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-[acetyl(methyl)amino]propanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: [(16Z,18Z)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-[acetyl(methyl)amino]propanoate
• 化学式: C₃₄H₄₆ClN₃O₁₀
• 分子量: 692.2
• InChiKey: WKPWGQKGSOKKOO-QGZZTLNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  48
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  157
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
  申请人：Genentech, Inc.

  公开号：US20160130358A1

  公开（公告）日：2016-05-12

  Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.

  通过突变母抗体的核酸序列并将一个或多个氨基酸残基替换为半胱氨酸以编码半胱氨酸工程抗体；表达半胱氨酸工程抗体；并分离半胱氨酸工程抗体，制备包含重链或轻链中的一个自由半胱氨酸氨基酸的半胱氨酸工程抗体。
• METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
  申请人：Genentech, Inc.

  公开号：US20160082120A1

  公开（公告）日：2016-03-24

  Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
• ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20170058032A1

  公开（公告）日：2017-03-02

  The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
• HINDERED DISULFIDE DRUG CONJUGATES
  申请人：Genentech, Inc.

  公开号：US20170112891A1

  公开（公告）日：2017-04-27

  The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.
• ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
  申请人：Genentech, Inc.

  公开号：US20170174782A1

  公开（公告）日：2017-06-22

  The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.